Sunday, January 29, 2023
  • Login
No Result
View All Result
The News Beam
  • Home
  • News
    • Politics
    • Business & Economy
    • Sports
    • Entertainment
    • Global
  • Development
    • Health
    • Education
    • MGDs
    • Development Agencies
  • Your Community
    • CDAs
    • LGAs
    • Projects
    • Community Champions
  • The Entrepreneur
    • Street Money
    • SMEs
    • Youthprenuers
    • Agriprenuers
    • Capacity Building
  • Specials
    • Lifestyle
    • Relationships
    • Books & Arts
    • Faith
    • Teens World
    • Guest Columnists
The News Beam
  • Home
  • News
    • Politics
    • Business & Economy
    • Sports
    • Entertainment
    • Global
  • Development
    • Health
    • Education
    • MGDs
    • Development Agencies
  • Your Community
    • CDAs
    • LGAs
    • Projects
    • Community Champions
  • The Entrepreneur
    • Street Money
    • SMEs
    • Youthprenuers
    • Agriprenuers
    • Capacity Building
  • Specials
    • Lifestyle
    • Relationships
    • Books & Arts
    • Faith
    • Teens World
    • Guest Columnists
No Result
View All Result
The News Beam
Home DEVELOPMENT Health

Vaccine Against Covid-19 Infection discovered

November 9, 2020
in Health, Global, News
Reading Time: 3 mins read
0
A A
0
Vaccine Against Covid-19 Infection discovered
Share on FacebookShare on Twitter

An American pharmaceutical corporation, Pfizer Inc. has announced it’s vaccine’s ability to prevent COVID-19 which has proven to be more than 90% effective against the virus.

The Chairman and CEO of Pfizer, Dr. Albert Bourla announced this in a press release today, 9th of November 2020, saying, “Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19″.

He further said that, “We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen. With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis. We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks.”

An evaluable count which was conducted reached a total of 94 cases where the DMC performed its first analysis on all the cases. The case which was split between vaccinated individuals and those who received the placebo have indicated a vaccine efficacy rate above 90%, meaning that after the initiation of the vaccination which consists of a 2-dose schedule, the vaccine has a-28-day protection against the virus.

The release also noted that the DMC has not reported any serious safety concerns and recommends that the study continue to collect additional safety and efficacy data as planned. The data will be discussed with regulatory authorities worldwide.

BioNTech’s co-founder and CEO, Prof. Ugur Sahin also said that, “The first interim analysis of our global Phase 3 study provides evidence that a vaccine may effectively prevent COVID-19. This is a victory for innovation, science and a global collaborative effort.”

He revealed that, “When we embarked on this journey 10 months ago this is what we aspired to achieve. Especially today, while we are all in the midst of a second wave and many of us in lockdown, we appreciate even more how important this milestone is on our path towards ending this pandemic and for all of us to regain a sense of normality. We will continue to collect further data as the trial continues to enroll for a final analysis planned when a total of 164 confirmed COVID-19 cases have accrued. I would like to thank everyone who has contributed to make this important achievement possible.”

The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,538 participants to date, 38,955 of whom have received a second dose of the vaccine candidate as of November 8, 2020. Approximately 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds. The trial is continuing to enroll and is expected to continue through the final analysis when a total of 164 confirmed COVID-19 cases have accrued.

The study also will evaluate the potential for the vaccine candidate to provide protection against COVID-19 in those who have had prior exposure to SARS-CoV-2, as well as vaccine prevention against severe COVID-19 disease.

Pfizer Inc. is an American pharmaceutical corporation headquartered in New York City. In 2012, it was one of the world’s largest pharmaceutical companies and ranked 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.The company has made the second-largest pharmaceutical settlement with the United States Department of Justice.

The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology. Its products include the blockbuster drug Lipitor (atorvastatin), used to lower LDL blood cholesterol; Lyrica (pregabalin) for neuropathic pain and fibromyalgia; Diflucan (fluconazole), an oral antifungal medication; Zithromax (azithromycin), an antibiotic; Viagra (sildenafil) for erectile dysfunction; and Celebrex (also Celebra, celecoxib), an anti-inflammatory drug.

Read Also: 50 Global Health-tech Innovators To Solve Africa’s Healthcare Challenges- IFC

Tags: COVID-19
ShareTweetSend
Previous Post

Here Are The Main Reasons PENGASSAN Is On Strike

Next Post

WAEC Says Circumstances Beyond it’s Control Caused Change In Timetable for Private Candidates

Related Posts

Inflation in December 2022
News

What you need to know: December inflation rate at   21.34%

January 16, 2023
18
Business Risks Forecasts
Business & Economy

How to Protect Your Business from Top Risks in 2023

November 15, 2022
50
eNaira: CBN lists 7 benefits to Nigerians, economy
Business & Economy

eNaira: CBN lists 7 benefits to Nigerians, economy

November 10, 2022
25
NDIC Logo
Business & Economy

NDIC To Bank Customers: “Come and Collect Your Remaining Funds in 20 Closed Banks”

November 8, 2022
11
CBN Head Office
Business & Economy

CBN to withdraw 200, 500 and 1000 bank notes from January 2023. Circulate New Notes From December 2022

October 26, 2022
287
Mohammad Mahmood Abubakar, Minister of Agriculture and Rural Development
News

N18bn Bush Clearing saga: Agric ministry refutes allegation, says N2.5bn spent for land preparation

August 18, 2022
14
Next Post
WAEC Says Circumstances Beyond it's Control Caused Change In Timetable for Private Candidates

WAEC Says Circumstances Beyond it's Control Caused Change In Timetable for Private Candidates

VIDEO! DJ Cuppy Gifts herself an Expensive Pre-Birtday Gift; See it here

VIDEO! DJ Cuppy Gifts herself an Expensive Pre-Birtday Gift; See it here

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

I agree to the Terms & Conditions and Privacy Policy.

  • Trending
  • Comments
  • Latest
How to Apply for the N25 Billion Youth Investment Fund of the Federal Govt

How to Apply for the N25 Billion Youth Investment Fund of the Federal Govt

October 16, 2020
Covid-19: See List of Vaccination Centers in Lagos State

Covid-19: See List of Vaccination Centers in Lagos State

August 19, 2021
Banks suffer 11% reduction in new loans as customers resist interest rate hike

CBN reveals 9 Business Categories that recorded Increased Activity This Month

9
BREAKING ! How Hurriedly installed Application Saved Central Bank of Nigeria website from 'Anonymous' hack

BREAKING ! How Hurriedly installed Application Saved Central Bank of Nigeria website from ‘Anonymous’ hack

7
Inflation in December 2022

What you need to know: December inflation rate at   21.34%

January 16, 2023
Business Risks Forecasts

How to Protect Your Business from Top Risks in 2023

November 15, 2022

Categories

  • Agriprenuers (12)
  • Books & Arts (7)
  • Business & Economy (434)
  • Capacity Building (25)
  • CDAs (2)
  • Community Champions (1)
  • Crime (196)
  • DEVELOPMENT (74)
  • Development Agencies (109)
  • Economy (317)
  • Education (192)
  • Entertainment (405)
  • Faith (55)
  • Finance (335)
  • Global (103)
  • Guest Columnists (17)
  • Health (56)
  • Health (242)
  • Industry (149)
  • LGAs (1)
  • Lifestyle (98)
  • MGDs (10)
  • News (2,292)
  • Politics (373)
  • Projects (2)
  • Relationships (70)
  • Security (164)
  • SMEs (15)
  • SPECIALS (87)
  • Sports (311)
  • Street Money (9)
  • Tech (138)
  • Teens World (3)
  • The Entrepreneur (26)
  • Uncategorized (70)
  • Your Community (33)
  • Youthprenuers (14)
No Result
View All Result
News
Politics
Business & Economy
Sports
Entertainment
Global

Development

Health
Education
MGDs
Development Agencies

Your Community

CDAs
LGAs
Projects
Community Champions

The Entrepreneur

Street Money
SMEs
Youthprenuers
Agriprenuers
Capacity Building

Specials

Lifestyle
Relationships
Books & Arts
Faith
Teens World
Guest Columnists

Follow Us

  • About Us
  • Contact Us
  • Terms of Usage
  • Privacy Policy
  • Advert Rates
  • Newsletters
  • Resources
  • Submit a Story
No Result
View All Result
  • Home
  • News
    • Politics
    • Business & Economy
    • Sports
    • Entertainment
    • Global
  • Development
    • Health
    • Education
    • MGDs
    • Development Agencies
  • Your Community
    • CDAs
    • LGAs
    • Projects
    • Community Champions
  • The Entrepreneur
    • Street Money
    • SMEs
    • Youthprenuers
    • Agriprenuers
    • Capacity Building
  • Specials
    • Lifestyle
    • Relationships
    • Books & Arts
    • Faith
    • Teens World
    • Guest Columnists
  • Login

© 2020 The News Beam is the highest circulated and most read newspaper in Nigeria. The online portal of The News Beam is the most visited website in the world.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.

Subscribe With The News Beam